• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by OmniAb Inc.

    9/10/25 4:35:27 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $OABI alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0001846253
    Avista Public Acquisition Corp. II
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    OmniAb, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
       Over Five Years Ago
    X Within Last Five Years (Specify Year) 2022
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    OmniAb, Inc.
    Street Address 1 Street Address 2
    5980 HORTON STREET SUITE 600
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    EMERYVILLE CALIFORNIA 94608 510-250-7800

    3. Related Persons

    Last Name First Name Middle Name
    Foehr Matthew W.
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gustafson Kurt
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Berkman Charles
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Higgins John
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cochran Jennifer
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Bertozzi Carolyn R.
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Love Steve
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Crouse Steve
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gotwals Philip J.
    Street Address 1 Street Address 2
    5980 Horton Street, Suite 600
    City State/Province/Country ZIP/PostalCode
    Emeryville CALIFORNIA 94608
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
    X Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
       Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-08-26    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
       Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
       Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Leerink Partners LLC 39011
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    53 State Street, 40th Floor
    City State/Province/Country ZIP/Postal Code
    Boston MASSACHUSETTS 02109
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
    X All States
       Foreign/non-US

    13. Offering and Sales Amounts

    Total Offering Amount $29,998,991 USD
    or    Indefinite
    Total Amount Sold $29,998,991 USD
    Total Remaining to be Sold $0 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    15

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $1,799,939 USD
       Estimate
    Finders' Fees $0 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    OmniAb, Inc. /s/ Charles Berkman Charles Berkman Secretary 2025-09-10

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $OABI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OABI

    DatePrice TargetRatingAnalyst
    11/29/2023$6.00Outperform
    RBC Capital Mkts
    4/21/2023$8.00Buy
    The Benchmark Company
    4/13/2023$10.00Buy
    Craig Hallum
    2/22/2023$10.00Outperform
    Cowen
    2/13/2023$11.00Buy
    H.C. Wainwright
    More analyst ratings

    $OABI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OmniAb to Participate at the H.C. Wainwright 27th Annual Global Investment Conference

    OmniAb, Inc. (NASDAQ:OABI) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference taking place September 8-10, 2025 at the Lotte New York Palace Hotel. Management will be available for one-on-one meetings on Tuesday, September 9th with investors registered for the event. Investors interested in scheduling a meeting with OmniAb management should contact their H.C. Wainwright representative, or email [email protected]. About OmniAb® OmniAb licenses cutting edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology pl

    9/2/25 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Announces $30 Million Private Placement

    OmniAb, Inc. (NASDAQ:OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private placement to be approximately $30 million, before deducting any placement agent fees and offering-related expenses. The net proceeds from the financing are expected to be used by OmniAb for general corporate purposes. The private placement is expected to close on or about August 26, 2025, subject to customary closing conditions. The financing incl

    8/25/25 7:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. "Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team's execution, and puts us on pace for one of our strongest years ever in partner adds. Additionally, a recent further streamlining of our operations enhances the scalability and long-term value of our business," said Matt Foehr, Chief E

    8/6/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Foehr Matthew W was granted 540,540 shares, increasing direct ownership by 14% to 4,341,987 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    8/26/25 4:02:52 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven converted options into 20,000 shares, increasing direct ownership by 52% to 58,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    6/18/25 4:16:07 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Higgins John L converted options into 20,000 shares, increasing direct ownership by 0.71% to 2,851,887 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    6/18/25 4:14:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Cochran Jennifer R. bought $45,600 worth of shares (30,000 units at $1.52), increasing direct ownership by 26% to 145,274 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/15/25 4:02:17 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Love Steven bought $36,500 worth of shares (25,000 units at $1.46), increasing direct ownership by 188% to 38,333 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/14/25 5:04:09 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Higgins John L bought $93,600 worth of shares (65,000 units at $1.44), increasing direct ownership by 2% to 2,831,887 units (SEC Form 4)

    4 - OmniAb, Inc. (0001846253) (Issuer)

    5/13/25 5:52:02 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    SEC Filings

    View All

    SEC Form D filed by OmniAb Inc.

    D - OmniAb, Inc. (0001846253) (Filer)

    9/10/25 4:35:27 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - OmniAb, Inc. (0001846253) (Filer)

    8/25/25 7:05:25 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by OmniAb Inc.

    SCHEDULE 13G/A - OmniAb, Inc. (0001846253) (Subject)

    8/14/25 10:47:14 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on OmniAb with a new price target

    RBC Capital Mkts initiated coverage of OmniAb with a rating of Outperform and set a new price target of $6.00

    11/29/23 7:31:15 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    The Benchmark Company initiated coverage on OmniAb with a new price target

    The Benchmark Company initiated coverage of OmniAb with a rating of Buy and set a new price target of $8.00

    4/21/23 7:43:22 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Craig Hallum initiated coverage on OmniAb with a new price target

    Craig Hallum initiated coverage of OmniAb with a rating of Buy and set a new price target of $10.00

    4/13/23 9:08:06 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Leadership Updates

    Live Leadership Updates

    View All

    OmniAb Appoints Steve Love to its Board of Directors

    OmniAb, Inc. (NASDAQ:OABI) today announced the appointment of Steve Love to its Board of Directors. Mr. Love has more than 30 years of financial experience including more than 13 years serving in Chief Financial Officer positions, and will serve on OmniAb's Audit Committee as Chair. With this appointment the OmniAb Board returns to seven directors, including five independent directors. "We are delighted Steve has agreed to join the OmniAb Board of Directors and extend a warm welcome," stated John Higgins, OmniAb Board Chair. "Steve's vast financial expertise, technical knowledge and experience leading technology and biotechnology companies will be valuable assets as we grow and expand our

    11/1/23 9:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Financials

    Live finance-specific insights

    View All

    OmniAb Reports Second Quarter 2025 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three and six months ended June 30, 2025, and provided operating and partner program updates. "Our business is performing very well as we continued our momentum in partner additions in the second quarter, reaching 100 active partners. This is a testament to the strength of our innovative technology platform and to our team's execution, and puts us on pace for one of our strongest years ever in partner adds. Additionally, a recent further streamlining of our operations enhances the scalability and long-term value of our business," said Matt Foehr, Chief E

    8/6/25 4:05:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb to Report Second Quarter 2025 Financial Results on August 6

    OmniAb, Inc. (NASDAQ:OABI) will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. financial markets on Wednesday, August 6, 2025, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Conference Call and Webcast Information What:  OmniAb conference call to discuss second quarter 2025 financial results and business updates     Date:  Wednesday, August 6, 2025     Time:  4:30 p.m. Eastern time (1:30 p.m. Pacific time)     Phone: U.S. (800) 549 8228   International (289) 819 1520   Conference ID is 93102     Webcast: Live a

    7/16/25 8:00:00 AM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    OmniAb Reports First Quarter 2025 Financial Results and Business Highlights

    Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today OmniAb, Inc. (NASDAQ:OABI) today reported financial results for the three months ended March 31, 2025, and provided operating and partner program updates. "We have started the year with robust deal flow, including both platform and asset-based deals. Our business remains strong as our diversified pipeline of partner programs is progressing with recent and expected new clinical entrants and data readouts," said Matt Foehr, Chief Executive Officer of OmniAb. "Today we announced the xPloration® Partner Access Program for OmniAb partners, enhancing the scalability of our technology platforms and creating new business opportuni

    5/8/25 4:06:00 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $OABI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by OmniAb Inc.

    SC 13G/A - OmniAb, Inc. (0001846253) (Subject)

    11/14/24 4:06:53 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form SC 13D/A filed by OmniAb Inc.

    SC 13D/A - OmniAb, Inc. (0001846253) (Subject)

    7/2/24 5:00:16 PM ET
    $OABI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care